NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

Revenue from Germany would certainly be a positive, but revenue from German patients covered by insurance would be a much larger positive.

Revenue from self pay patients validates NW and Linda Powers, but revenue from German DCVax-L patients that are receiving insurance reimbursement validates DCVax-L efficacy. In fact, we might be able to infer what level of efficacy the German's assessed. That would be a tell on how long until DCVax-L gets approved here in the US.